ROSEN, TOP INVESTOR LAW FIRM, Alerts Ardelyx, Inc. Investors of Key Deadline in Securities Class Action - ARDX

NEW YORK, Sept. 21, 2024 (GLOBE NEWSWIRE) - ROSEN, a globally recognized law firm, reminds the investors of ARDX Ardelyx, Inc. that they have until October 15, 2024, to seek the role of lead plaintiff in a securities class action that has been filed against the company. This action is on behalf of shareholders who bought securities of Ardelyx between October 31, 2023, and July 1, 2024, inclusive (the "Class Period").

Understanding the Class Action

Investors who purchased ARDX Ardelyx, Inc.'s securities during the Class Period and suffered losses have the opportunity to lead the class action lawsuit. The lead plaintiff role is a critical position in the case and is responsible for representing the interests of all class members in directing the litigation. The deadline for applying to be a lead plaintiff is rapidly approaching, making it important for investors to act promptly.

About Ardelyx, Inc.

Ardelyx, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines that address the unmet needs in kidney and cardiorenal diseases. Based in Fremont, California, Ardelyx is committed to delivering life-changing treatments that improve the quality of life for patients in the United States and internationally.

Legal Recourse for Investors

ROSEN Law Firm stands as an advocate for investors' rights and specializes in securities class actions and shareholder derivative litigation. Investors who have been impacted by alleged securities fraud or a misleading prospectus have a limited time frame, known as the statute of limitations, to seek recovery of their financial losses through the courts. By joining the class action suit against Ardelyx, affected investors have a chance to recoup their losses.

ROSEN, Ardelyx, Investor